Diabetes News

Cellonis Biotechnologies, a Beijing and HK-based medical research and application company, has recorded some remarkable results in the treatment of a twelve-year-old boy with diabetes using their stem cell therapy in a Beijing partner hospital.

Business models for deploying near field communication mobile payments are evaluated in this report.

The Worldwide Glucose monitoring devices market is expected to be more than US$ 16 Billion by 2014. In addition, Roche Diagnostics & Life Scan together controlled 65% of the global glucose meter market in 2008.

Dear Dr. Gott: I'm an 83-year-old female. I take a weekly 70 milligrams alendronate sodium tablet for osteoporosis, 50 milligrams of blood-pressure medicine and 20 milligrams of a cholesterol medication. My doctor also ...

Los Angeles — Disrupted sleep patterns seem to contribute to the risk of obesity and diabetes, according to numerous studies. Researchers have theorized that disrupted circadian rhythms throw off various hormonal ...

The U.S. Food and Drug Administration's (FDA) Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee has completed their evaluation of the ...

A new study led by York University researchers finds that young athletes with Type 1 diabetes may experience a marked decrease in performance as a result of their blood sugar levels. The study, published in the ...

Faced with conflicting and less-than-conclusive scientific evidence, a majority of a Food and Drug Administration advisory panel voted Wednesday to recommend that the controversial diabetes drug Avandia remain on the ...

DAYTON — Local doctors and patients looking for a clear answer on the safety of the diabetes drug Avandia will have to settle for a mixed decision Wednesday, July 14, from an advisory panel of 33 experts at the U.S ...

A majority of the U.S. Food and Drug Administration's panel of outside experts voted to keep GlaxoSmithKline's ( GSK ) type 2 diabetes drug Avandia on the U.S. market, albeit with new restrictions. The vote is not a ...